32 results on '"Kabbinavar, Fairooz"'
Search Results
2. The Chromophobe Tumor Grading System is the Preferred Grading Scheme for Chromophobe Renal Cell Carcinoma
3. A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01)
4. Functional and Oncological Outcomes of Partial Nephrectomy of Solitary Kidneys
5. CA9 Gene: Single Nucleotide Polymorphism Predicts Metastatic Renal Cell Carcinoma Prognosis
6. Pathobiology and prognosis of chromophobe renal cell carcinoma
7. Tumor Size Does Not Predict Risk of Metastatic Disease or Prognosis of Small Renal Cell Carcinomas
8. The Chemokine Receptor CXCR3 is an Independent Prognostic Factor in Patients With Localized Clear Cell Renal Cell Carcinoma
9. Prognostic Impact of Tumor Size on pT2 Renal Cell Carcinoma: An International Multicenter Experience
10. Metachronous Bilateral Renal Cell Carcinoma: Risk Assessment, Prognosis and Relevance of the Primary-Free Interval
11. Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)
12. MP35-06 EFFECTS OF DENDRITIC CELL-BASED AD-GM∙CAIX VACCINE AS MONOTHERAPY OR IN COMBINATION WITH SUNITINIB IN AN IMMUNOCOMPETENT MOUSE MODEL OF METASTATIC RENAL CELL CARCINOMA
13. 2003 ANTITUMOR ACTIVITY OF SUNITINIB VERSUS OTHER FDA-APPROVED TARGETED CANCER AGENTS AGAINST METASTATIC RENAL CELL CARCINOMA IN THE FIRST-LINE SETTING
14. 2002 NON-CLEAR CELL HISTOLOGY IS INDEPENDENTLY ASSOCIATED WITH POOR OUTCOMES IN THE TARGETED THERAPY ERA
15. 979 UISS RISK STRATIFICATION CAN IDENTIFY PATIENTS LESS LIKELY TO BENEFIT FROM CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA
16. 572 CLINICAL, MOLECULAR AND GENETIC CORRELATES OF LYMPHATIC SPREAD IN CLEAR CELL RENAL CELL CARCINOMA
17. 437 GAIN OF CHROMOSOME 8Q IS ASSOCIATED WITH METASTASES AND POOR SURVIVAL OF PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA
18. 304 DC-AD-GMCAIX BASED VACCINE THERAPY IS SAFE AND EFFECTIVE IN IMMUNOCOMPETENT MURINE KIDNEY CANCER TUMOR MODELS
19. 1770 CANCER-SPECIFIC SURVIVAL OUTCOMES OF SUNITINIB TREATMENT IN UISS RISK-STRATIFIED METASTATIC RCC PATIENTS
20. RENAL FUNCTION AND LOCAL RECURRENCE AFTER PARTIAL NEPHRECTOMY IN SOLITARY KIDNEYS
21. MOLECULAR PROGNOSTIC TUMOR PROFILING OF TYPE 1 AND TYPE 2 PAPILLARY RENAL CELL CARCINOMA: RELEVANCE TO THE DEVELOPMENT OF TUMOR-SPECIFIC TARGETED THERAPIES
22. PAPILLARY RENAL CELL CARCINOMA WITH CLEAR CELLS – PATHOLOGICAL, IMMUNOHISTOCHEMICAL AND CYTOGENETIC CHARACTERISTICS OF A NOVEL ENTITY
23. GENDER SPECIFIC CYTOGENETIC SIGNATURES CAN DISTINGUISH BETWEEN ONCOCYTOMA AND CHROMOPHOBE RENAL CELL CARCINOMA
24. 1291: Prognostic Impact of Cytogenetic Findings in Clear Cell Renal Cell Carcinoma: Improved Survival is Seen in Patients with Loss of Chromosome 3P
25. 1255: Potential Role of Postoperative Azotemia in Predicting Response to Interleukin-2 (IL-2) Immunotherapy Following Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
26. 1254: Papillary Renal Cell Carcinoma: Natural Biology and Relevance of Subtyping
27. 1117: The Malignant Potential and Prognosis of Small Renal Tumors
28. 915: Prognosis and Survival of Synchronous Bilateral Renal Cell Carcinoma: A Multicenter Experience
29. 900: Loss of 3P, Loss of 9P and Trisomy 17 Predict Prognosis in Patients with Papillary Renal Cell Carcinoma
30. 492: Prospective Evaluation of Carbonic Anhydrase IX (CAIX) as a Molecular Marker in Metastatic Renal Cell Carcinoma: Interim Results
31. 494: The Chemokine Receptor CXCR3 is an Independent Prognostic Factor for Patients with Localized Clear Cell Renal Cell Carcinoma
32. 491: Molecular Tumor Profiling Improves Risk Assessment and Prognostication of Patients with Non-Metastatic Clear Cell Renal Cell Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.